The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB 2 receptor. The present invention further relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activities of both the CB 1 receptor and the CB 2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pain, for example bone and joint pain, muscle pain, dental pain, migraine and other headache pain, inflammatory pain, neuropathic pain, pain that occurs as an adverse effect of therapeutics and pain associated with osteoarthritis； hyperalgesia； allodynia； inflammatory hyperalgesia； neuropathic hyperalgesia； acute nociception； osteoporosis； multiple sclerosis-associated spasticity； autoimmune disorders； allergic reactions； CNS inflammation； atherosclerosis； undesired immune cell activity and inflammation； age-related macular degeneration； cough； leukemia； lymphoma； CNS tumors； prostate cancer； Alzheimer's disease； stroke-induced damage； dementia； amyotrophic lateral sclerosis, and Parkinson's disease.
